Towards early disease modification of Parkinson’s disease: a review of lessons learned in the Alzheimer field

Outcome measurement in functional neurological disorder: a systematic review and recommendations

(2020) Susannah Pick et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

LRRK2 in Parkinson disease: challenges of clinical trials

(2020) Eduardo Tolosa et al.   Nature Reviews Neurology

Disease modification and biomarker development in Parkinson disease

(2020) Alberto J. Espay et al.   NEUROLOGY

Cognitively unimpaired adults’ reactions to disclosure of amyloid PET scan results

(2020) Emily A. Largent et al.   PLoS One

Ambroxol for the Treatment of Patients With Parkinson Disease With and Without Glucocerebrosidase Gene Mutations

(2020) Stephen Mullin et al.   JAMA Neurology

Patients' views on the ethical challenges of early Parkinson disease detection

(2020) Eva Schaeffer et al.   NEUROLOGY

Revisiting protein aggregation as pathogenic in sporadic Parkinson and Alzheimer diseases

(2019) Alberto J. Espay et al.   NEUROLOGY

Emerging therapies in Parkinson disease — repurposed drugs and new approaches

(2019) Ahmad Elkouzi et al.   Nature Reviews Neurology

Prodromal Parkinson's Disease: The Decade Past, the Decade to Come

(2019) Ronald B. Postuma et al.   MOVEMENT DISORDERS

Predicting diagnosis of Parkinson's disease: A risk algorithm based on primary care presentations

(2019) Anette Schrag et al.   MOVEMENT DISORDERS

Persistent neuropathological effects 14 years following amyloid-β immunization in Alzheimer’s disease

(2019) James A R Nicoll et al.   BRAIN

CSF and blood biomarkers for Parkinson's disease

(2019) Lucilla Parnetti et al.   LANCET NEUROLOGY

Measuring Parkinson's disease over time: The real‐world within‐subject reliability of the MDS‐UPDRS

(2019) Luc J.W. Evers et al.   MOVEMENT DISORDERS

Increasing Comparability and Utility of Gut Microbiome Studies in Parkinson’s Disease: A Systematic Review

(2019) Jeffrey M. Boertien et al.   Journal of Parkinsons Disease

Effectiveness of home-based and remotely supervised aerobic exercise in Parkinson's disease: a double-blind, randomised controlled trial

(2019) Nicolien M van der Kolk et al.   LANCET NEUROLOGY

European Prevention of Alzheimer's Dementia Registry: Recruitment and prescreening approach for a longitudinal cohort and prevention trials

(2018) Lisa Vermunt et al.   Alzheimers & Dementia

NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease

(2018) Clifford R. Jack et al.   Alzheimers & Dementia

The End of the Beginning of the Alzheimer’s Disease Nightmare: A Devil’s Advocate’s View

(2018) Anders Wimo   JOURNAL OF ALZHEIMERS DISEASE

Targeted Therapies for Parkinson's Disease: From Genetics to the Clinic

(2018) S. Pablo Sardi et al.   MOVEMENT DISORDERS

Comprehension of an Elevated Amyloid Positron Emission Tomography Biomarker Result by Cognitively Normal Older Adults

(2018) Jessica Mozersky et al.   JAMA Neurology

Safety and Tolerability of Multiple Ascending Doses of PRX002/RG7935, an Anti–α-Synuclein Monoclonal Antibody, in Patients With Parkinson Disease

(2018) Joseph Jankovic et al.   JAMA Neurology

On the reconceptualization of Alzheimer’s disease

(2018) Maartje H. N. Schermer et al.   BIOETHICS

Therapies to Slow, Stop, or Reverse Parkinson’s Disease

(2018) Tom Foltynie et al.   Journal of Parkinsons Disease

Therapeutic approaches to target alpha-synuclein pathology

(2017) Patrik Brundin et al.   EXPERIMENTAL NEUROLOGY

Immunization with α-synuclein/Grp94 reshapes peripheral immunity and suppresses microgliosis in a chronic Parkinsonism model

(2017) Javier Villadiego et al.   GLIA

Why do so many clinical trials of therapies for Alzheimer's disease fail?

(2017) Roy M Anderson et al.   LANCET

Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial

(2017) Dilan Athauda et al.   LANCET

Safety and immunogenicity of the tau vaccine AADvac1 in patients with Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase 1 trial

(2017) Petr Novak et al.   LANCET NEUROLOGY

Strategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers

(2017) Giovanni B Frisoni et al.   LANCET NEUROLOGY

Validation of the MDS research criteria for prodromal Parkinson's disease: Longitudinal assessment in a REM sleep behavior disorder (RBD) cohort

(2017) Seyed-Mohammad Fereshtehnejad et al.   MOVEMENT DISORDERS

T cells from patients with Parkinson’s disease recognize α-synuclein peptides

(2017) David Sulzer et al.   NATURE

Small-molecule PET Tracers for Imaging Proteinopathies

(2017) Chester A. Mathis et al.   SEMINARS IN NUCLEAR MEDICINE

Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria

(2016) Bruno Dubois et al.   Alzheimers & Dementia

New concepts in the pathogenesis and presentation of Parkinsons disease

(2016) A. Sauerbier et al.   CLINICAL MEDICINE

Predicting Parkinson disease in the community using a nonmotor risk score

(2016) Sirwan K. L. Darweesh et al.   EUROPEAN JOURNAL OF EPIDEMIOLOGY

Development of a Standardized Approach to Disclosing Amyloid Imaging Research Results in Mild Cognitive Impairment

(2016) Jennifer H. Lingler et al.   JOURNAL OF ALZHEIMERS DISEASE

First-in-human assessment of PRX002, an anti-α-synuclein monoclonal antibody, in healthy volunteers

(2016) Dale B. Schenk et al.   MOVEMENT DISORDERS

Technology in Parkinson's disease: Challenges and opportunities

(2016) Alberto J. Espay et al.   MOVEMENT DISORDERS

Genetic risk of Parkinson’s disease in the general population

(2016) Sirwan K.L. Darweesh et al.   PARKINSONISM & RELATED DISORDERS

Insulin resistance and Parkinson’s disease: A new target for disease modification?

(2016) D. Athauda et al.   PROGRESS IN NEUROBIOLOGY

Solanezumab and the amyloid hypothesis for Alzheimer’s disease

(2016) David G Le Couteur et al.   BMJ-British Medical Journal

Solanezumab and the amyloid hypothesis for Alzheimer’s disease

(2016) David G Le Couteur et al.   BMJ-British Medical Journal

MDS research criteria for prodromal Parkinson's disease

(2015) Daniela Berg et al.   MOVEMENT DISORDERS

Development of a process to disclose amyloid imaging results to cognitively normal older adult research participants

(2015) Kristin Harkins et al.   Alzheimers Research & Therapy

Immunotherapy in Parkinson’s Disease: Micromanaging Alpha-Synuclein Aggregation

(2015) Sonia George et al.   Journal of Parkinsons Disease

Cerebrospinal fluid alpha-synuclein as a biomarker for Parkinson's disease diagnosis: a systematic review and meta-analysis

(2014) Liang Gao et al.   INTERNATIONAL JOURNAL OF NEUROSCIENCE

Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease

(2014) Stephen Salloway et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease

(2014) Rachelle S. Doody et al.   NEW ENGLAND JOURNAL OF MEDICINE

The A4 Study: Stopping AD Before Symptoms Begin?

(2014) R. A. Sperling et al.   Science Translational Medicine

Designing drug trials for Alzheimer’s disease: What we have learned from the release of the phase III antibody trials: A report from the EU/US/CTAD Task Force

(2013) Bruno Vellas et al.   Alzheimers & Dementia

Reduced α-synuclein levels in cerebrospinal fluid in Parkinson's disease are unrelated to clinical and imaging measures of disease severity

(2013) K. D. van Dijk et al.   EUROPEAN JOURNAL OF NEUROLOGY

Delayed emergence of a parkinsonian disorder or dementia in 81% of older men initially diagnosed with idiopathic rapid eye movement sleep behavior disorder: a 16-year update on a previously reported series

(2013) Carlos H. Schenck et al.   SLEEP MEDICINE

Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis

(2012) Reisa Sperling et al.   LANCET NEUROLOGY

Identifying prodromal Parkinson's disease: Pre-Motor disorders in Parkinson's disease

(2012) Ronald B. Postuma et al.   MOVEMENT DISORDERS

Neuropathology underlying clinical variability in patients with synucleinopathies

(2011) Glenda M. Halliday et al.   ACTA NEUROPATHOLOGICA

A critical evaluation of the Braak staging scheme for Parkinson's disease

(2008) Robert E. Burke et al.   ANNALS OF NEUROLOGY

Red Blood Cells Are the Major Source of Alpha-Synuclein in Blood

(2008) Robin Barbour et al.   Neurodegenerative Diseases